Natera Inc (NTRA) Stock Price, Quote & News

Company Profile

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples und...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 650 980 9190

Website: www.natera.com

Address:

13011 McCallen Pass, Building A Suite 100, Austin, United States

Noah17 Nov. 16 at 9:29 PM

$NTRA Trending

0 · Reply

biolover Nov. 16 at 8:34 PM

$VKTX Druckenmiller top position is in biotechs $NTRA and $INSM ..Just tell you the guy sees potential in biotech more than all tech. That what you need to know at this time as he is very good in macro analysis. ( obviously biotech was dismal a year ago ). But like most generalists he is going after commercial biotech primarily as he knows his limitation in predicting trials outcome. I would not sell one share in VK to move to the other two as the potential with vk is several folds that of anything that is commercial and pumped by bio hedge funds. Just do u deep dd and spend time on understanding these to feel comfortable.

1 · Reply

thelattehq Nov. 16 at 4:01 PM

$NVDA $NTRA $SYK https://www.thelattehq.com/p/a-market-looking-for-direction

0 · Reply

jaydilks Nov. 16 at 11:17 AM

$DNA Stan Druckenmiller just made a big investment in $NTRA in the past quarter. Quite large by his standards. There are some similarities as Natera was a SPAC in 2015 and Ginkgo Bioworks in 2021. Is DNA just on a 6 year lag? Could be. https://x.com/next100baggers/status/1989739418975179195?s=61

1 · Reply

erevnon Nov. 13 at 4:19 PM

Stephens & Co. maintains Natera $NTRA at Overweight and raises the price target from $197 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

JarvisFlow Nov. 13 at 2:37 PM

Stephens & Co. has adjusted their stance on Natera ( $NTRA ), setting the rating to Overweight with a target price of 197 → 235.

0 · Reply

smartkarma Nov. 13 at 6:28 AM

$NTRA | Primer: Natera Inc (NTRA US) - Nov 2025 "Natera is a leader in the high-growth cell-free DNA (cfDNA) testing market, with a strong portfolio spanning women's health (Panorama), oncology..." - αSK (Smartkarma) Read more: https://www.smartkarma.com/insights/primer-natera-inc-ntra-us-nov-2025

0 · Reply

WAJeff Nov. 12 at 4:00 PM

$NTRA $212.21 ath

0 · Reply

OmenOfSilentLoss Nov. 11 at 6:12 PM

$NTRA Earnings could be today Nov 11. NXXT has Vanguard 1,049,265 and JPMorgan 23,241 ready. Undervalued at 3 to 4x while peers fetch higher. Multiple expansion is your upside

0 · Reply

erevnon Nov. 11 at 5:45 PM

Piper Sandler maintains Natera $NTRA at Overweight and raises the price target from $220 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Natera Integrates with Flatiron Health's OncoEMR® Platform

Nov 6, 2025, 8:36 PM EST - 10 days ago

Natera, Inc. (NTRA) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 10 days ago

Natera Reports Third Quarter 2025 Financial Results

Oct 31, 2025, 7:00 AM EDT - 16 days ago

Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT

Oct 30, 2025, 7:00 AM EDT - 17 days ago

Natera to Report its Third Quarter Results on November 6, 2025

Oct 28, 2025, 7:00 AM EDT - 19 days ago

Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity

Oct 27, 2025, 6:20 AM EDT - 20 days ago

Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 23, 2025, 3:57 PM EDT - 24 days ago

Natera, Inc. (NTRA) Discusses Findings from ESMO Congress Transcript

Oct 20, 2025, 1:05 AM EDT - 27 days ago

Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients

Oct 16, 2025, 8:00 AM EDT - 4 weeks ago

Natera Named to Fast Company's Next Big Things in Tech List

Oct 13, 2025, 8:00 AM EDT - 4 weeks ago

Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings

Oct 12, 2025, 6:10 PM EDT - 5 weeks ago

Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium

Oct 1, 2025, 8:00 AM EDT - 6 weeks ago

Enrollment Tops 1,600 in Natera's EXPAND Trial of Single Gene NIPT

Sep 30, 2025, 8:00 AM EDT - 6 weeks ago

Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer

Sep 29, 2025, 8:00 AM EDT - 6 weeks ago

Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows

Sep 24, 2025, 10:53 AM EDT - 7 weeks ago

Natera, Inc. (NTRA) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Sep 15, 2025, 10:10 AM EDT - 2 months ago

Can Natera Stock Reach $500?

Sep 10, 2025, 12:31 PM EDT - 2 months ago

Natera, Inc. (NTRA) Presents At Baird Global Healthcare Conference 2025 Transcript

Sep 2, 2025, 2:40 PM EDT - 2 months ago

Natera: A Buy As Positive Growth And Cashflow Outweigh Unprofitability

Aug 29, 2025, 8:18 AM EDT - 2 months ago

Natera Provides Update on Patent Litigation with NeoGenomics

Aug 28, 2025, 8:00 AM EDT - 2 months ago

Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer

Aug 25, 2025, 8:00 AM EDT - 2 months ago

Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer

Aug 22, 2025, 6:04 AM EDT - 3 months ago

Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine

Aug 22, 2025, 5:00 AM EDT - 3 months ago

Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation

Aug 18, 2025, 6:00 AM EDT - 3 months ago

IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit

Aug 8, 2025, 4:08 PM EDT - 3 months ago

Natera shares surge 17% after strong Q2 results and upgraded guidance

Aug 7, 2025, 10:43 PM EDT - 3 months ago

Natera, Inc. (NTRA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 3 months ago

Natera Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 7:00 AM EDT - 3 months ago

Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions

Aug 1, 2025, 7:00 AM EDT - 3 months ago

Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations

Jul 31, 2025, 7:00 AM EDT - 3 months ago

Natera to Report Its Second Quarter Results on August 7, 2025

Jul 29, 2025, 7:00 AM EDT - 3 months ago

Natera Announces Launch of ABCSG 61 (“TEODOR”), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer

Jul 24, 2025, 8:00 AM EDT - 4 months ago

PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT

Jul 7, 2025, 7:00 AM EDT - 4 months ago

Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer

Jul 1, 2025, 4:05 PM EDT - 4 months ago

Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD

Jun 4, 2025, 7:00 AM EDT - 5 months ago

Natera Announces Medicare Coverage for Signatera™ Genome

Jun 2, 2025, 4:05 PM EDT - 5 months ago

SignateraTM Genome Clinical Performance Highlighted at ASCO 2025

May 22, 2025, 5:08 PM EDT - 6 months ago

Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting

May 16, 2025, 8:41 AM EDT - 6 months ago

Natera: The Clues In Q1 Earnings

May 8, 2025, 8:58 PM EDT - 6 months ago

Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 6 months ago

Natera Reports First Quarter 2025 Financial Results

May 8, 2025, 10:30 AM EDT - 6 months ago

Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress

May 7, 2025, 7:00 AM EDT - 6 months ago

Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows

May 5, 2025, 7:00 AM EDT - 6 months ago

Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera

May 1, 2025, 7:00 AM EDT - 7 months ago

Natera to Report its First Quarter Results on May 8, 2025

Apr 29, 2025, 4:05 PM EDT - 7 months ago

Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction

Apr 29, 2025, 11:45 AM EDT - 7 months ago

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

ACLX ISRG MASI MCK PEN TMO UNH

Apr 24, 2025, 7:00 AM EDT - 7 months ago

Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test

Apr 22, 2025, 4:05 PM EDT - 7 months ago

Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting

Mar 25, 2025, 7:00 AM EDT - 8 months ago

DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

Noah17 Nov. 16 at 9:29 PM

$NTRA Trending

0 · Reply

biolover Nov. 16 at 8:34 PM

1 · Reply

thelattehq Nov. 16 at 4:01 PM

$NVDA $NTRA $SYK https://www.thelattehq.com/p/a-market-looking-for-direction

0 · Reply

jaydilks Nov. 16 at 11:17 AM

1 · Reply

erevnon Nov. 13 at 4:19 PM

Stephens & Co. maintains Natera $NTRA at Overweight and raises the price target from $197 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

JarvisFlow Nov. 13 at 2:37 PM

Stephens & Co. has adjusted their stance on Natera ( $NTRA ), setting the rating to Overweight with a target price of 197 → 235.

0 · Reply

smartkarma Nov. 13 at 6:28 AM

0 · Reply

WAJeff Nov. 12 at 4:00 PM

$NTRA $212.21 ath

0 · Reply

OmenOfSilentLoss Nov. 11 at 6:12 PM

$NTRA Earnings could be today Nov 11. NXXT has Vanguard 1,049,265 and JPMorgan 23,241 ready. Undervalued at 3 to 4x while peers fetch higher. Multiple expansion is your upside

0 · Reply

erevnon Nov. 11 at 5:45 PM

Piper Sandler maintains Natera $NTRA at Overweight and raises the price target from $220 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

JarvisFlow Nov. 11 at 5:08 PM

Piper Sandler updates rating for Natera ( $NTRA ) to Overweight, target set at 220 → 230.

0 · Reply

JarvisFlow Nov. 11 at 4:48 PM

Morgan Stanley updates rating for Natera ( $NTRA ) to Overweight, target set at 195 → 220.

0 · Reply

Woodman7 Nov. 11 at 1:43 PM

$EXAS - took a look at the Price/Sales valuations now that we are through the 3Q reporting period. Per YF: $GH 13.3x $NTRA 13.2x $GRAL 20.0x $EXAS 4.0x

2 · Reply

WAJeff Nov. 10 at 7:13 PM

$NTRA $210 ath

0 · Reply

BEATOFtheMARKET Nov. 9 at 10:34 PM

$NSC $NTAP $NTRA $NTSX $NU

0 · Reply

Doozio Nov. 8 at 8:14 PM

$NTRA FRYday 🧠 🚀 bar after the Thursday 🐑 hangover 🐒🍌🧠⏰♾️

1 · Reply

Cheetah007 Nov. 8 at 12:47 PM

$NTRA so much potential. If management team continue to be able to monetize this tech. It's the biotech tesla.

0 · Reply

JarvisFlow Nov. 7 at 9:54 PM

Canaccord Genuity has updated their rating for Natera ( $NTRA ) to Buy with a price target of 250.

0 · Reply

JarvisFlow Nov. 7 at 8:05 PM

JP Morgan has updated their rating for Natera ( $NTRA ) to Overweight with a price target of 240.

0 · Reply

JarvisFlow Nov. 7 at 6:53 PM

Wells Fargo updates rating for Natera ( $NTRA ) to Equal-Weight, target set at 175 → 190.

0 · Reply

JarvisFlow Nov. 7 at 3:42 PM

Barclays has updated their rating for Natera ( $NTRA ) to Overweight with a price target of 230.

0 · Reply

erevnon Nov. 7 at 3:15 PM

Evercore ISI Group maintains Natera $NTRA at Outperform and raises the price target from $190 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Market Cap	28.19B
Revenue (ttm)	1.70B
Net Income (ttm)	-190.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-11.22%
Debt to Equity Ratio	0.06

Volume	1,289,000
Avg Vol	1,230,806
Day's Range	N/A - N/A
Shares Out	138.01M
Stochastic %K	74%
Beta	1.75
Analysts	Strong Sell
Price Target	$224.84